MIDLOTHIAN, Va., Oct. 22 /PRNewswire/ -- At CHEST 2008, PARI Respiratory Equipment will present a comparative study of three commercially available, breath-enhanced nebulizers and their in-vitro performance and delivery efficiency of budesonide inhalation suspension (Pulmicort Respules, AstraZeneca).
"Our goal in testing various breath-enhanced nebulizers is to help clinicians consider respirable drug delivery rate to ensure patients receive clinically effective doses," said Lisa Cambridge, director of clinical development for PARI Respiratory Equipment, Inc.
The study compares the LC Sprint Reusable Nebulizer (PARI Respiratory Equipment), LC PLUS Reusable Nebulizer (PARI Respiratory Equipment), and Sidestream Plus reusable nebulizer (Respironics). Ms. Cambridge will present the results on October 28th at 1pm in Philadelphia, PA at CHEST 2008, the annual meeting of the American College of Chest Physicians.
About PARI Respiratory Equipment, Inc.
PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them.
Maker of the world's leading breath-enhanced reusable nebulizer, the PARI LC PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufactures the award winning PARI TREK S compact compressor, Bubbles the Fish II aerosol mask, and durable PARI PRONEB Ultra II. PARI's Vortex anti-static valved holding chamber improves the aerosol deposition of metered dose inhalers (MDI's). PARI's North American headquarters is in Midlothian, VA with worldwide headquarters in Starnberg, Germany. Online at http://www.Pari.com
Additional information is available by contacting Ayars & Associates at 805-845-5682 or Ashley Weigand at 804-253-7274 x711.
|SOURCE PARI Respiratory Equipment, Inc.|
Copyright©2008 PR Newswire.
All rights reserved